This purpose of this observational study is to review medical chart and patient survey data collection within an early access to medicines scheme (EAMS) program. Participant who are eligible, provide consent and enroll into the squamous cell oesophageal cancer EAMS to receive Nivolumab will be included in this study.
Study Type
OBSERVATIONAL
Enrollment
87
Participants will receive Nivolumab after prior chemotherapy as part of an early access to medicines scheme (EAMS) program in the United Kingdom (UK)
Distribution of demographic characteristics of NSCLC participants treated with nivolumab at initiation of nivolumab treatment: Age
Time frame: At baseline
Distribution of demographic characteristics of NSCLC participants treated with nivolumab at initiation of nivolumab treatment: Gender
Time frame: At baseline
Distribution of demographic characteristics of NSCLC participants treated with nivolumab at initiation of nivolumab treatment: Race
Time frame: At baseline
Distribution of demographic characteristics of NSCLC participants treated with nivolumab at initiation of nivolumab treatment: Eastern Cooperative Oncology Group Performance Status (ECOG PS)
Time frame: At baseline
Distribution of demographic characteristics of NSCLC participants treated with nivolumab at initiation of nivolumab treatment: Condition which the product is being used for
Time frame: At baseline
Distribution of demographic characteristics of NSCLC participants treated with nivolumab at initiation of nivolumab treatment: Number of organs with metastases
Time frame: At baseline
Distribution of demographic characteristics of NSCLC participants treated with nivolumab at initiation of nivolumab treatment: Sites of metastasis
Time frame: At baseline
Distribution of demographic characteristics of NSCLC participants treated with nivolumab at initiation of nivolumab treatment: Prior surgery for oesophageal cancer
Time frame: At baseline
Distribution of demographic characteristics of NSCLC participants treated with nivolumab at initiation of nivolumab treatment: Underlying comorbidities
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Local Institution - 0006
Truro, Cornwall, United Kingdom
Local Institution
London, Greater London, United Kingdom
Local Institution
Maidstone, Kent, United Kingdom
Local Institution
Glasgow, Lanarkshire, United Kingdom
Local Institution
Grimsby, Lincolnshire, United Kingdom
Local Institution
Edinburgh, Scotland, United Kingdom
Local Institution
Birmingham, West Midlands, United Kingdom
Local Institution
Leeds, West Yorkshire, United Kingdom
Local Institution
Basingstoke, United Kingdom
Local Institution
Bebington, United Kingdom
...and 26 more locations
Time frame: At baseline
Distribution of demographic characteristics of NSCLC participants treated with nivolumab at initiation of nivolumab treatment: Concomitant medication
Time frame: At baseline
Distribution of demographic characteristics of NSCLC participants treated with nivolumab at initiation of nivolumab treatment: Weight
Time frame: At baseline
Distribution of demographic characteristics of NSCLC participants treated with nivolumab at initiation of nivolumab treatment: Disease history
Time frame: At baseline
Distribution of demographic characteristics of NSCLC participants treated with nivolumab at initiation of nivolumab treatment: Treatment history
Time frame: At baseline
Distribution of treatment patterns of nivolumab: Treatment duration
Time frame: Up to 12 months
Distribution of disease progression to determine progression free survival (PFS) based on data collected as part of routine care
Time frame: Up to 12 months
Distribution of disease progression to determine overall survival (OS) based on data collected as part of routine care
Time frame: Up to 12 months
Distribution of survival status to determine progression free survival (PFS) based on data collected as part of routine care
Time frame: Up to 12 months
Distribution of survival status to determine overall survival (OS) based on data collected as part of routine care
Time frame: Up to 12 months
Distribution of patient quality of life through EQ-5D-3L (EQ-5D) at baseline following patient enrolment into the EAMS
Time frame: At baseline
Distribution of patient quality of life through EQ-5D-3L (EQ-5D) every two weeks for 24 weeks post-treatment initiation following patient enrolment into the EAMS
Time frame: Up to 24 weeks